Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives

Research output: Contribution to journalArticle

Standard

Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives. / Jeffery, Hannah; Braitch, Manjit; Brown, Solomon; Oo, Ye Htun.

In: Frontiers in immunology, Vol. 7, 334, 06.09.2016.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{79496a179fed454090c79564446cfc7a,
title = "Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives",
abstract = "The increasing demand for liver transplantation and the decline in donor organs has highlighted the need for alternative novel therapies to prevent chronic active hepatitis, which eventually leads to liver cirrhosis and liver cancer. Liver histology of chronic hepatitis is composed of both effector and regulatory lymphocytes. The human liver contains different subsets of effector lymphocytes that are kept in check by a subpopulation of T cells known as Regulatory T cells (Treg). The balance of effector and regulatory lymphocytes generally determines the outcome of hepatic inflammation: resolution, fulminant hepatitis, or chronic active hepatitis. Thus, maintaining and adjusting this balance is crucial in immunological manipulation of liver diseases. One of the options to restorethis balance is to enrich Treg in the liver disease patients. Advances in the knowledge of Treg biology and development of clinical grade isolation reagents, cell sorting equipment, and good manufacturing practice facilities have paved the way to apply Treg cells as a potential therapy to restore peripheral self-tolerance in autoimmune liver diseases (AILD), chronic rejection, and posttransplantation. Past and on-going studies have applied Treg in type-1 diabetes mellitus, systemic lupus erythematosus, graft versus host diseases, and solid organ transplantations. There have not been any new therapies for the AILDfor more than three decades; thus, the clinical potential for the application of autologous Treg cell therapy to treat autoimmune liver disease is an attractive and novel option. However, it is fundamental to understand the deep immunology, genetic profiles, biology, homing behavior, and microenvironment of Treg before applying the cells to the patients.",
keywords = "regulatory T cells, microenvironment, metabolites, microbes",
author = "Hannah Jeffery and Manjit Braitch and Solomon Brown and Oo, {Ye Htun}",
note = "Article was submitted to Immunotherapies and Vaccines, a section of the journal Froniters in Immunology",
year = "2016",
month = sep,
day = "6",
doi = "10.3389/fimmu.2016.00334",
language = "English",
volume = "7",
journal = "Frontiers in immunology",
issn = "1664-3224",
publisher = "Frontiers",

}

RIS

TY - JOUR

T1 - Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives

AU - Jeffery, Hannah

AU - Braitch, Manjit

AU - Brown, Solomon

AU - Oo, Ye Htun

N1 - Article was submitted to Immunotherapies and Vaccines, a section of the journal Froniters in Immunology

PY - 2016/9/6

Y1 - 2016/9/6

N2 - The increasing demand for liver transplantation and the decline in donor organs has highlighted the need for alternative novel therapies to prevent chronic active hepatitis, which eventually leads to liver cirrhosis and liver cancer. Liver histology of chronic hepatitis is composed of both effector and regulatory lymphocytes. The human liver contains different subsets of effector lymphocytes that are kept in check by a subpopulation of T cells known as Regulatory T cells (Treg). The balance of effector and regulatory lymphocytes generally determines the outcome of hepatic inflammation: resolution, fulminant hepatitis, or chronic active hepatitis. Thus, maintaining and adjusting this balance is crucial in immunological manipulation of liver diseases. One of the options to restorethis balance is to enrich Treg in the liver disease patients. Advances in the knowledge of Treg biology and development of clinical grade isolation reagents, cell sorting equipment, and good manufacturing practice facilities have paved the way to apply Treg cells as a potential therapy to restore peripheral self-tolerance in autoimmune liver diseases (AILD), chronic rejection, and posttransplantation. Past and on-going studies have applied Treg in type-1 diabetes mellitus, systemic lupus erythematosus, graft versus host diseases, and solid organ transplantations. There have not been any new therapies for the AILDfor more than three decades; thus, the clinical potential for the application of autologous Treg cell therapy to treat autoimmune liver disease is an attractive and novel option. However, it is fundamental to understand the deep immunology, genetic profiles, biology, homing behavior, and microenvironment of Treg before applying the cells to the patients.

AB - The increasing demand for liver transplantation and the decline in donor organs has highlighted the need for alternative novel therapies to prevent chronic active hepatitis, which eventually leads to liver cirrhosis and liver cancer. Liver histology of chronic hepatitis is composed of both effector and regulatory lymphocytes. The human liver contains different subsets of effector lymphocytes that are kept in check by a subpopulation of T cells known as Regulatory T cells (Treg). The balance of effector and regulatory lymphocytes generally determines the outcome of hepatic inflammation: resolution, fulminant hepatitis, or chronic active hepatitis. Thus, maintaining and adjusting this balance is crucial in immunological manipulation of liver diseases. One of the options to restorethis balance is to enrich Treg in the liver disease patients. Advances in the knowledge of Treg biology and development of clinical grade isolation reagents, cell sorting equipment, and good manufacturing practice facilities have paved the way to apply Treg cells as a potential therapy to restore peripheral self-tolerance in autoimmune liver diseases (AILD), chronic rejection, and posttransplantation. Past and on-going studies have applied Treg in type-1 diabetes mellitus, systemic lupus erythematosus, graft versus host diseases, and solid organ transplantations. There have not been any new therapies for the AILDfor more than three decades; thus, the clinical potential for the application of autologous Treg cell therapy to treat autoimmune liver disease is an attractive and novel option. However, it is fundamental to understand the deep immunology, genetic profiles, biology, homing behavior, and microenvironment of Treg before applying the cells to the patients.

KW - regulatory T cells

KW - microenvironment

KW - metabolites

KW - microbes

U2 - 10.3389/fimmu.2016.00334

DO - 10.3389/fimmu.2016.00334

M3 - Article

VL - 7

JO - Frontiers in immunology

JF - Frontiers in immunology

SN - 1664-3224

M1 - 334

ER -